{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:43:09Z","timestamp":1711845789431},"reference-count":34,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2024]]},"DOI":"10.3960\/jslrt.23046","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T22:15:40Z","timestamp":1711577740000},"page":"45-51","source":"Crossref","is-referenced-by-count":0,"title":["Extranodal NK\/T-cell lymphoma with localized relapse in bone marrow of lower leg detected using PET-CT"],"prefix":"10.3960","volume":"64","author":[{"given":"Takahisa","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiro","family":"Tatetsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kawanaka","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Imakane","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyu","family":"Sonoda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Shichijo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kennosuke","family":"Karube","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory\u00a0Medicine,\u00a0Graduate School of Medicine,\u00a0Nagoya University, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Mikami","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kisato","family":"Nosaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichirou","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Alaggio R, Amador C, Anagnostopoulos I, <i>et al.<\/i> The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36: 1720-1748.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Suzuki R, Suzumiya J, Yamaguchi M <i>et al.<\/i> Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010; 21: 1032-1040.","DOI":"10.1093\/annonc\/mdp418"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Tse E, Zhao WL, Xiong J, Kwong YL. How we treat NK\/T-cell lymphomas. J Hematol Oncol. 2022; 15: 74.","DOI":"10.1186\/s13045-022-01293-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Kim SJ, Yoon DH, Jaccard A <i>et al.<\/i> A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016; 17: 389-400.","DOI":"10.1016\/S1470-2045(15)00533-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Lim SH, Hong JY, Lim ST <i>et al.<\/i> Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol. 2017; 28: 2199-2205.","DOI":"10.1093\/annonc\/mdx316"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Miyazaki K, Suzuki R, Oguchi M <i>et al.<\/i> Long\u2010term outcomes and central nervous system relapse in extranodal natural killer\/T\u2010cell lymphoma. Hematol Oncol. 2022; 40: 667-677.","DOI":"10.1002\/hon.2977"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Yamaguchi M, Tobinai K, Oguchi M <i>et al.<\/i> Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009; 27: 5594-5600.","DOI":"10.1200\/JCO.2009.23.8295"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Yamaguchi M, Kwong YL, Kim WS <i>et al.<\/i> Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011; 29: 4410-4416.","DOI":"10.1200\/JCO.2011.35.6287"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Wang JJ, Dong M, He XH <i>et al.<\/i> GDP (Gemcitabine, Dexamethasone, and Cisplatin) is highly effective and well-tolerated for newly diagnosed stage IV and relapsed\/refractory extranodal natural killer\/T-cell lymphoma, nasal type. Medicine (Baltimore). 2016; 95: e2787.","DOI":"10.1097\/MD.0000000000002787"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type. Blood. 2018; 131: 2528-2540.","DOI":"10.1182\/blood-2017-12-791418"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 He X, Gao Y, Li Z, Huang H. Review on natural killer\/T\u2010cell lymphoma. Hematol Oncol. 2023; 41: 221-229.","DOI":"10.1002\/hon.2944"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Tse E, Kwong YL. How I treat NK\/T-cell lymphomas. Blood. 2013; 121: 4997-5005.","DOI":"10.1182\/blood-2013-01-453233"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Yamaguchi M, Suzuki R, Miyazaki K <i>et al.<\/i> Improved prognosis of extranodal NK\/T cell lymphoma, nasal type of nasal origin but not extranasal origin. Ann Hematol. 2019; 98: 1647-1655.","DOI":"10.1007\/s00277-019-03689-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Yamaguchi M, Suzuki R, Oguchi M <i>et al.<\/i> Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: A cooperative study in Japan. J Clin Oncol. 2017; 35: 32-39.","DOI":"10.1200\/JCO.2016.68.1619"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Cheson BD, Fisher RI, Barrington SF <i>et al.<\/i> Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32: 3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Moon SH, Cho SK, Kim WS <i>et al.<\/i> The role of 18F-FDG PET\/CT for initial staging of nasal type natural killer\/T-cell lymphoma: a comparison with conventional staging methods. J Nucl Med. 2013; 54: 1039-1044.","DOI":"10.2967\/jnumed.112.113399"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Khong PL, Pang CBY, Liang R, Kwong YL, Au WY. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008; 87: 613-621.","DOI":"10.1007\/s00277-008-0494-8"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Chan WKS, Au WY, Wong CYO <i>et al.<\/i> Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas. Clin Nucl Med. 2010; 35: 571-575.","DOI":"10.1097\/RLU.0b013e3181e4dcbf"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Jiang C, Zhang X, Jiang M <i>et al.<\/i> Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET\/CT in extranodal natural killer\/T-cell lymphoma, nasal type. Ann Nucl Med. 2015; 29: 442-451.","DOI":"10.1007\/s12149-015-0964-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Kim CY, Hong CM, Kim DH <i>et al.<\/i> Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET\/CT in patients with extranodal NK\/T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013; 40: 1321-1329.","DOI":"10.1007\/s00259-013-2443-6"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Ko KY, Liu CJ, Ko CL, Yen RF. Intratumoral heterogeneity of pretreatment 18F-FDG PET images predict disease progression in patients with nasal type extranodal natural killer\/T-cell lymphoma. Clin Nucl Med. 2016; 41: 922-926.","DOI":"10.1097\/RLU.0000000000001375"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Jiang C, Liu J, Li L <i>et al.<\/i> Predictive approaches for post-therapy PET\/CT in patients with extranodal natural killer\/T-cell lymphoma: a retrospective study. Nucl Med Commun. 2017; 38: 937-947.","DOI":"10.1097\/MNM.0000000000000731"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Chang Y, Fu X, Sun Z <i>et al.<\/i> Utility of baseline, interim and end-of-treatment 18F-FDG PET\/CT in extranodal natural killer\/T-cell lymphoma patients treated with L-asparaginase\/pegaspargase. Sci Rep. 2017; 7: 41057.","DOI":"10.1038\/srep41057"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Li YJ, Li ZM, Xia XY <i>et al.<\/i> Prognostic value of interim and posttherapy 18F-FDG PET\/CT in patients with mature T-cell and natural killer cell lymphomas. J Nucl Med. 2013; 54: 507-515.","DOI":"10.2967\/jnumed.112.110262"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Jiang C, Su M, Kosik RO <i>et al.<\/i> The Deauville 5-point scale improves the prognostic value of interim FDG PET\/CT in extranodal natural killer\/T-cell lymphoma. Clin Nucl Med. 2015; 40: 767-773.","DOI":"10.1097\/RLU.0000000000000892"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Khong PL, Huang B, Lee EY, Chan WK, Kwong YL. Midtreatment 18F-FDG PET\/CT scan for early response assessment of smile therapy in natural killer\/T-cell lymphoma: A prospective study from a single center. J Nucl Med. 2014; 55: 911-916.","DOI":"10.2967\/jnumed.113.131946"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Qin C, Yang S, Sun X <i>et al.<\/i> 18F-FDG PET\/CT for prognostic stratification of patients with extranodal natural killer\/T-cell lymphoma. Clin Nucl Med. 2019; 44: 201-208.","DOI":"10.1097\/RLU.0000000000002440"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Chen X, Zhao S, Wang H <i>et al.<\/i> Assessment of the prognostic value of interim fluorodeoxyglucose positron emission tomography\/computed tomography in nasal-type extranodal natural killer\/T-cell lymphoma. Quant Imaging Med Surg. 2021; 11: 1220-1233.","DOI":"10.21037\/qims-20-620"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 El-Galaly TC, d\u2019Amore F, Mylam KJ <i>et al.<\/i> Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012; 30: 4508-4514.","DOI":"10.1200\/JCO.2012.42.4036"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Khan AB, Barrington SF, Mikhaeel NG <i>et al.<\/i> PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013; 122: 61-67.","DOI":"10.1182\/blood-2012-12-473389"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Yang C, Wu W, Zhou H <i>et al.<\/i> 18F-FDG PET\/CT plays a limited role in replacing bone marrow biopsy for newly diagnosed advanced-stage patients with extranodal natural killer\/T-cell lymphoma. Front Oncol. 2022; 12: 894804.","DOI":"10.3389\/fonc.2022.894804"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Zhou Z, Chen C, Li X <i>et al.<\/i> Evaluation of bone marrow involvement in extranodal NK\/T cell lymphoma by FDG-PET\/CT. Ann Hematol. 2015; 94: 963-967.","DOI":"10.1007\/s00277-014-2289-4"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Koh Y, Lee JM, Woo GU <i>et al.<\/i> FDG PET for Evaluation of bone marrow status in T-cell lymphoma. Clin Nucl Med. 2019; 44: 4-10.","DOI":"10.1097\/RLU.0000000000002320"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Wang Y, Xie L, Tian R <i>et al.<\/i> PET\/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer\/T-cell lymphoma. J Cancer Res Clin Oncol. 2019; 145: 2529-2539.","DOI":"10.1007\/s00432-019-02957-5"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/1\/64_23046\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T05:45:00Z","timestamp":1711777500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/1\/64_23046\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23046","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"23046"}}